Eli Lilly and Company $LLY Shares Sold by Vestcor Inc

Key Points

• Vestcor Inc trimmed its position in Eli Lilly by 11.6% in Q3, selling 3,775 shares and ending the period with 28,728 shares valued at about $21.92 million, representing roughly 0.7% of Vestcor’s portfolio and its 29th largest holding.
• Eli Lilly reported a quarterly beat with $7.54 EPS and $19.29 billion revenue (up 42.6% year-over-year) and set FY2026 guidance of 33.50–35.00 EPS; analysts have mostly raised targets and ratings, giving an average price target of about $1,229.59 and a consensus "Moderate Buy."

Vestcor Inc decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 28,728 shares of the company's stock after selling 3,775 shares during the period. Eli Lilly and Company comprises about 0.7% of Vestcor Inc's investment portfolio, making the stock its 29th biggest holding. Vestcor Inc's holdings in Eli Lilly and Company were worth $21,919,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after acquiring an additional 11,396 shares in the last quarter. Rede Wealth LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $487,000. Central Pacific Bank Trust Division raised its position in shares of Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock valued at $6,859,000 after purchasing an additional 1,843 shares during the period. Cidel Asset Management Inc. lifted its stake in shares of Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after buying an additional 5,591 shares during the last quarter. Finally, Oak Family Advisors LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $1,979,000. Institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Argus raised their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Berenberg Bank upped their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a report on Thursday, February 19th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Finally, Barclays started coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They issued an "overweight" rating and a $1,350.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $1,229.59.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $990.58 on Monday. The stock has a market cap of $934.47 billion, a P/E ratio of 43.16, a PEG ratio of 1.15 and a beta of 0.40. The company's 50-day simple moving average is $1,045.63 and its 200 day simple moving average is $942.56. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same quarter last year, the company earned $5.32 earnings per share. The company's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.